Drugs / Gelofusine

Trials 3 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT02541734 Aug 2015 → May 2017 type 2 diabetes mellitus Radboud University Medical Center Completed No outcome recorded
Phase not applicable2 trials
NCT05647057 Jul 2023 → Jul 2024 Amsterdam UMC, location VUmc Completed No outcome recorded
NCT02461329 May 2015 → Sep 2016 bleeding disorder, vascular-type, blood platelet disease Kratochvil Milan, MD Unknown No outcome recorded
Also used as a comparator or background therapy in 5 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03246659 Background Aug 2016 → Nov 2018 medullary thyroid gland carcinoma Paola Anna Erba Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00773110 Comparator Dec 2008 → May 2011 autoinflammatory syndrome Imperial College London Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT02808325 Comparator Jun 2016 → Jun 2017 dehydration polycythemia B. Braun Medical SA Completed No outcome recorded
Phase not applicable2 trials
NCT02071524 Comparator Sep 2013 → Mar 2017 Università degli Studi di Ferrara Unknown No outcome recorded
NCT01935791 Background Jul 2013 → Nov 2018 metabolic disease Imperial College London Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Gelofusine Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid)” NCT00773110
7

“Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)” NCT02071524

“receiving an infusion of gelofusineNCT01935791

NCT05647057

NCT03246659

NCT02541734

NCT02461329

NCT02808325

Known as succinylated gelatin “One of these agents is succinylated gelatin (Gelofusine), a plasma expander that consists of a mixture of collagen-derived peptides.” NCT02541734
Modality Other / unclassified “Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid)” NCT00773110
Route Intravenous “infusion via intravenous boluses” NCT02461329